Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-15.57%
operating margin TTM
16.37%
revenue TTM
204.77 Million
revenue per share TTM
1.03$
valuation ratios | |
|---|---|
| pe ratio | -4.54 |
| peg ratio | -0.07 |
| price to book ratio | -0.60 |
| price to sales ratio | 0.73 |
| enterprise value multiple | 11.83 |
| price fair value | -0.60 |
profitability ratios | |
|---|---|
| gross profit margin | 79.35% |
| operating profit margin | 16.37% |
| pretax profit margin | -15.57% |
| net profit margin | -15.57% |
| return on assets | -15.05% |
| return on equity | 14.81% |
| return on capital employed | 55.75% |
liquidity ratio | |
|---|---|
| current ratio | 1.37 |
| quick ratio | 0.99 |
| cash ratio | 0.59 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 502.68 |
| operating cycle | 590.70 |
| days of payables outstanding | 274.77 |
| cash conversion cycle | 315.93 |
| receivables turnover | 4.15 |
| payables turnover | 1.33 |
| inventory turnover | 0.73 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.87 |
| debt equity ratio | -0.77 |
| long term debt to capitalization | -1.57 |
| total debt to capitalization | -3.27 |
| interest coverage | 0.92 |
| cash flow to debt ratio | -0.08 |
cash flow ratios | |
|---|---|
| free cash flow per share | -0.13 |
| cash per share | 0.76 |
| operating cash flow per share | -0.12 |
| free cash flow operating cash flow ratio | 1.01 |
| cash flow coverage ratios | -0.08 |
| short term coverage ratios | -0.43 |
| capital expenditure coverage ratio | -74.62 |
Frequently Asked Questions
When was the last time Esperion Therapeutics, Inc. (NASDAQ:ESPR) reported earnings?
Esperion Therapeutics, Inc. (ESPR) published its most recent earnings results on 07-11-2024.
What is Esperion Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Esperion Therapeutics, Inc. (NASDAQ:ESPR)'s trailing twelve months ROE is 14.81%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Esperion Therapeutics, Inc. (ESPR) currently has a ROA of -15.05%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did ESPR's net profit margin stand at?
ESPR reported a profit margin of -15.57% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is ESPR's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 1.37 in the most recent quarter. The quick ratio stood at 0.99, with a Debt/Eq ratio of -0.77.